Chris’ note: As 2020 winds down, we’re zooming in on the year’s best insights from the team of analysts here at Legacy Research.
One of the biggest profit opportunities we’ve been tracking for you is in disruptive tech. That’s why today, you’ll hear from Silicon Valley insider and our tech expert here at Legacy, Jeff Brown.
Jeff has been ahead of the curve on tech megatrends such as the 5G rollout and the electric vehicle revolution. And he has given his readers the chance to lock in gains of 239%… 259%… and 278%.
But right now, Jeff is most excited about a different tech trend.
Using artificial intelligence and other bleeding-edge tech, breakthroughs in biotech that would have previously taken years are now happening in days.
As Jeff explains below in an essay he originally published in June, it’s ushering in a “golden age” of biotech profits…
There’s no going “back to normal.”
My longtime readers already know this… but COVID-19 has changed our world forever.
It’s easy to spot some of the changes.
Many of us are working remotely. We’re shopping online. And we’re rethinking how to hold conferences and public gatherings.
But there are less obvious changes, too…
Breakthroughs in biotechnology that were 5 to 10 years away… are now happening on a monthly or weekly basis.
We’re at the start of a multiyear bull market in biotech. The pandemic has opened the doors for radically new ways to make vaccines and therapies. Many of these weren’t taken seriously before.
This will help us cure diseases at a pace we’ve previously never seen.
For investors, it presents a once-in-a-generation opportunity to create enormous wealth.
When we picture biotechnology firms, we tend to think of scientists in white lab coats fiddling with test tubes and peering under microscopes.
But this story is far more interesting than that.
As I like to tell my readers, biotech is much more “tech” than “bio” these days.
Today, the biotech industry is using big data, machine learning, and artificial intelligence (AI) to make breakthroughs that would have seemed impossible even just a few years ago.
Consider just one example…
Back in March, the early stage biotech firm AbCellera did something many people previously thought was impossible.
It got a blood sample from a patient who had recovered from COVID-19. It used AI to screen more than 5 million immune cells in that sample. And it identified about 500 antibodies that helped the patient fight the virus.
Identifying these antibodies could be the key to treating COVID-19. AbCellera used this as a starting point to create an antibody therapy to potentially cure people with the disease.
Normally, this would take years. It took AbCellera just 11 days. Beyond incredible.
And the industry took notice…
Pharmaceutical giant Eli Lilly rushed to partner with AbCellera. They worked on a treatment using these antibodies.
Earlier this month, AbCellera became the first company to send its COVID-19 antibody therapy to clinical trials.
If these clinical trials go well, the company could receive emergency use authorization from the U.S. Food and Drug Administration (FDA). That will allow AbCellera to offer its therapy to the public in time for the fall.
That’s important, because we will see a second wave of COVID-19 cases as the weather gets cool and dry again.
Let’s think about this for a minute…
An early stage biotech company took blood samples and identified COVID-19 antibodies. It then developed a therapy and launched clinical trials. And it did all this in the span of four months. Until just recently, this process would have taken years.
This is revolutionary work.
In the decades I’ve been following the biotech industry, I’ve never seen this type of speed from it.
It’s thanks in large part to COVID-19. The virus has lit a fire under this overlooked industry. And it shows how scientists can apply breakthroughs in other tech, such as AI, to the biotech industry in ways they haven’t before.
Investors are starting to notice…
Suddenly, the world has woken up to the potential of biotechnology.
Every venture capitalist and private equity house has realized how powerful these technologies are and how quickly biotech can move. We’re going to see an acceleration in biotech investment, early stage companies, and initial public offerings (IPOs) as a result.
In fact, we’re already seeing that.
Just over half of all traditional IPOs this year have been biotech companies. Collectively, they’ve raised nearly $5 billion for drug development.
The 2020s will be the decade of biotech. This will be the first decade in which biotech firms truly harness the power of Moore’s Law (the roughly doubling of computing power every two years) and demonstrate exponential growth.
So as investors, we need to pay attention.
Think of it this way…
In early 2017, bitcoin was a mostly unknown, niche asset. That was just as mainstream investors were starting to get involved. It ran 2,000% higher versus the dollar that year.
I believe investors’ awareness and engagement in early stage biotech companies will rival that of the last cryptocurrency bull market.
But unlike cryptocurrencies – almost all of which are backed by nothing – early stage biotech is supported by very real, world-changing technology. The returns we will see from quality biotech companies will create lasting, generational wealth.
We’re at the very beginning of a multiyear biotech bull market. Breakthroughs will continue to happen. Diseases – previously thought untreatable – will be cured. And yes, fortunes will be made.
We’re entering a golden age of biotechnology. And it’s happening right now.
Regards,
Jeff Brown
Editor, Exponential Tech Investor
Chris’ note: What Jeff said in June still rings true. We’re at the start of a renaissance of biotech, genetic editing, and therapeutic development. And Jeff and his team at Brownstone Research are committed to bringing their readers investment advice that will allow them to profit from this renaissance for years to come.
For more on how to unlock the power of exponential growth in your portfolio, go right here.